Abbott announced a strategic collaboration with Novo Nordisk India to commercialize Extensior®? for people living with type 2 diabetes. This partnership leverages Novo Nordisk's scientific leadership in GLP-1s and Abbott's strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves.
Extensior®? is a second brand of Ozempic®?, the world's most prescribed GLP-1 RA (receptor agonist) molecule. Extensior®?
are approved as an adjunct to diet and exercise for adults with type 2 diabetes and is a GLP-1 RA recognized for offering the broadest range of benefits for people with this condition. Semaglutide, the molecule in Extensior®?, has demonstrated powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes. Semaglutide has demonstrated safety and efficacy through 44+ robust clinical trials and 10+ real-world studies across type 2 diabetes, obesity, heart, liver and kidney disease.
It has been on the market globally for close to a decade and has more than 49 million patient years of use across all semaglutide products. Extensior®? will be introduced in India as part of Abbott's expanding portfolio of advanced diabetes solutions and is expected to be available for Indian patients soon.
Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
